You can read the full article at Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial In a phase 3 trial conducted in Japan, the efficacy and safety of tirzepatide, a new medication for type 2 diabetes, were compared to dulaglutide
These factors are adversely hindering the market growth
As far as the time of day thats best to take a vitamin D supplement, there isnt any research that says morning or night is better
Have you ever wondered how some therapies are able to accelerate healing, reduce inflammation, and improve recovery at a deeper biological level
GHK-Cu is a signalling peptide, not a structural one